Stock ownership · SEC 13F · Q1 2025

LYELL IMMUNOPHARMA

Who owns LYELL IMMUNOPHARMA (CUSIP 55083R104)? A look at the institutions behind it, how tightly they hold it, and the latest quarter's moves.

$151K
Reported value
3
Institutions
100%
Top-5 share

The verdict

As of Q1 2025, 3 institutions report $151K in LYELL IMMUNOPHARMA positions, ownership that is dominated by its top few institutional owners.

3
institutions hold it
$151K
reported 13F value
100%
held by top 5

Based on long positions reported to the SEC as of Q1 2025; 13F omits shorts, options and non-US holdings.

How 13F ownership is computed · All tracked stocks · Concentration rankings

SEC Form 13F-HR ownership desk

CUSIP 55083R104 · Q1 2025 $0M reported

VALUE-TRACE · HOLDERS-FOCUS · CONC-DOM · PHOTO-UNK · ACTIVITY-MID · BOOK-SHORT

  • VALUE-TRACE $0.2M
  • HOLDERS-FOCUS 3 filers
  • CONC-DOM 100% top-5
  • PHOTO-UNK No peer
  • ACTIVITY-MID 3 new
  • BOOK-SHORT 3Q history

Read with: Ownership concentration guide - LYELL IMMUNOPHARMA's top-five holders account for 100% of reported value — read concentration before treating any single filer as a signal.

Largest institutional holders of LYELL IMMUNOPHARMA
  1. 1
    RHUMBLINE ADVISERS $127K
  2. 2
    JONES FINANCIAL COMPANIES LLLP $22K
  3. 3
    STRS OHIO $3K

Top 3 reported holders by value · Q1 2025

Top Institutional Holders

# Institution Shares Value Share of reported
1 RHUMBLINE ADVISERS 235,694 $127K 83.9%
2 JONES FINANCIAL COMPANIES LLLP 40,000 $22K 14.3%
3 STRS OHIO 5,100 $3K 1.8%

Investment Discretion

SEC Form 13F requires each institutional filer to report whether it exercises sole or shared discretion over a position. Among LYELL IMMUNOPHARMA's reported holders for Q1 2025, by reported value:

Sole discretion (SOLE)
100.0%

Latest Quarter Activity · Q1 2025

New positions (3)

RHUMBLINE ADVISERS $127K
JONES FINANCIAL COMPANIES LLLP $22K
STRS OHIO $3K

Complete exits (1)

Jefferies Financial Group Inc. (JEF) exited

Frequently Asked Questions

How many institutions hold LYELL IMMUNOPHARMA?▼
LYELL IMMUNOPHARMA is held by 3 institutional investors per the latest SEC Form 13F filings as of Q1 2025.
What is the total institutional value of LYELL IMMUNOPHARMA?▼
Institutions report $151K of LYELL IMMUNOPHARMA as of Q1 2025.
How concentrated is ownership of LYELL IMMUNOPHARMA?▼
The top five institutional holders account for 100% of the reported institutional value in LYELL IMMUNOPHARMA, making ownership dominated by its top few institutional owners.
Who is the largest institutional holder of LYELL IMMUNOPHARMA?▼
RHUMBLINE ADVISERS is the largest reported holder of LYELL IMMUNOPHARMA with $127K across 235,694 shares as of Q1 2025.

Source: U.S. Securities and Exchange Commission (SEC) - EDGAR Form 13F-HR institutional holdings filings · Q1 2025 13F-HR discloses long US-listed equity positions of managers with $100M+ qualifying assets, filed within 45 days of period end. Short positions and most derivatives are not disclosed.

PlainFundData is rendered directly from SEC EDGAR Form 13F-HR institutional holdings filings, no number is typed in by an editor. Holder lists, concentration, and reported value on this page are aggregated live from those 13F-HR extracts. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-05-16.